REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma

07 Apr 2024 15:00:12 By Nasdaq GlobeNewswire

Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024

01 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Regeneron Provides Update on Biologics License Application for Odronextamab

25 Mar 2024 06:00:02 By Nasdaq GlobeNewswire

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

12 Mar 2024 20:30:22 By Nasdaq GlobeNewswire

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

11 Mar 2024 06:00:23 By Nasdaq GlobeNewswire

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

08 Mar 2024 06:00:26 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

28 Feb 2024 08:48:56 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

26 Feb 2024 08:48:37 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

23 Feb 2024 08:45:04 By NetDania Notify

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation

23 Feb 2024 00:00:00 By Nasdaq GlobeNewswire

Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

21 Feb 2024 06:00:13 By Nasdaq GlobeNewswire

Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

15 Feb 2024 23:59:00 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

06 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

02 Feb 2024 08:45:10 By NetDania Notify

Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

02 Feb 2024 05:30:01 By Nasdaq GlobeNewswire

Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

02 Feb 2024 05:00:04 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

31 Jan 2024 08:45:04 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

30 Jan 2024 08:50:53 By NetDania Notify

Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

30 Jan 2024 06:00:41 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

26 Jan 2024 08:47:16 By NetDania Notify